This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
recently in Novartis Pharmaceuticals Corp. Accord Healthcare Inc. But in Novartis Pharmaceuticals v. Accord Healthcare, neither of the panel members in the majority of the original opinion even agreed to rehear the case, let alone agreed to reverse their prior ruling. Talk about snatching victory from the jaws of defeat!
Supreme Court’s reasoning in Helsinn Healthcare v. Teva Pharmaceuticals (2019), the Federal Circuit rejected Celanese’s contentions that statutory changes wrought by the America Invents Act (AIA) altered the on-sale bar such that sales of products manufactured by an undisclosed process would not invalidate patents claiming that process.
Court of Appeals for the Federal Circuit issued a precedential decision in Novartis Pharmaceuticals Corp. Accord Healthcare, Inc. Earlier today, the U.S. granting a petition for rehearing from appellant HEC Pharm Co.,
Healthcare and Pharma Consolidation: With regulatory shifts and technological advancements in biotech, pharmaceutical mergers are increasing, driven by both innovation and cost-saving incentives. Poor governance can also lead to litigation risks if sensitive data is mismanaged. The solution?
On April 29, the United States Court of Appeals for the Federal Circuit (CAFC) affirmed in part, reversed in part, vacated in part, and remanded a decision of the United States District Court for the Northern District of Illinois regarding alleged infringement by U.S. Venture Inc., Sunoco).
Such capabilities are essential for addressing the challenges of cross-border litigation and vast data volumes, ensuring higher efficiency and accuracy. UnitedLex appointed Renee Meisel as its new CEO, signaling a shift toward bolstered leadership aimed at driving innovation across its litigation and compliance offerings.
They had pharmaceutical companies, chemical companies, oil and gas companies, you name it, I have them as my clients. Anything that becomes much more transactional or litigation or anything like that is of course moves over to the realm of the attorney. And it didn’t matter what the what the company was all about.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content